Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir (JNJ-53718678) in Infants with RSV
NCT04068792Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of rilematovir in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04068792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068792.